


# ChemComm

Chemical Communications

[www.rsc.org/chemcomm](http://www.rsc.org/chemcomm)



ISSN 1359-7345



COMMUNICATION

Thomas Böttcher *et al.*

Synthetic quinolone signal analogues inhibiting the virulence factor elastase of *Pseudomonas aeruginosa*

**175** YEARS



Cite this: *Chem. Commun.*, 2016, 52, 13440

Received 29th July 2016,  
Accepted 23rd September 2016

DOI: 10.1039/c6cc06295d

[www.rsc.org/chemcomm](http://www.rsc.org/chemcomm)

## Synthetic quinolone signal analogues inhibiting the virulence factor elastase of *Pseudomonas aeruginosa*<sup>†</sup>

Dávid Szamosvári, Valentin F. Reichle, Monica Jureschi and Thomas Böttcher\*

We explore the chemical space of *Pseudomonas* quinolone signal analogs as privileged structures and report the discovery of a thienoquinolone as a potent inhibitor of the important virulence factor elastase of the human pathogen *Pseudomonas aeruginosa*. We provide evidence that the derivative binds to the active site zinc of elastase and additionally acts as a fluorescent zinc sensor.

*Pseudomonas aeruginosa* is an important opportunistic human pathogen responsible for severe diseases ranging from urinary tract infections *via* life-threatening sepsis, endocarditis, and meningitis to chronic respiratory infections in cystic fibrosis patients.<sup>1,2</sup> The increasing emergence of multi-drug resistant strains of *P. aeruginosa* poses major threats to public health and *P. aeruginosa* is one of the leading causes of hospital-acquired infections worldwide.<sup>3</sup> The pathogenicity of *P. aeruginosa* is mediated by its enormous arsenal of virulence factors including toxins, extracellular enzymes, siderophores, and secretion systems that directly inject virulence factors into the eukaryotic host cell.<sup>4</sup> A major virulence factor hereby is the enzyme elastase (LasB) that supports the infection and colonization process by damaging tissue and degrading immune proteins.<sup>5</sup> The fine-tuned production of virulence factors that is responsible for the pathogen's broad spectrum of infective life-styles is orchestrated by the interactions of several intertwined quorum sensing systems.<sup>6–8</sup> Inhibition of quorum sensing and its downstream circuits has attracted much attention as potential strategy to disarm pathogens for the future treatment of infectious diseases.<sup>9–12</sup> One of the quorum sensing systems of *P. aeruginosa*, the *Pseudomonas* quinolone signalling (*pqs*) system, uses a series of 2-alkyl-4-quinolones (AQs) as signalling molecules.<sup>13</sup> While various different AQs are known, the most abundant and well-studied are 3-hydroxy-2-heptyl-4-quinolone (PQS) and its biosynthetic precursor 2-heptyl-4-quinolone (HHQ) that may both have distinct roles in cell-to-cell communication.<sup>14,15</sup>

PQS and HHQ have been demonstrated to regulate virulence factor expression of *P. aeruginosa* and it has thus been suggested that targeting the *pqs* system may be a promising anti-virulence strategy.<sup>16,17</sup> Furthermore, the HHQ and PQS quinolone scaffolds represent chemically privileged structures and we hence reasoned that heteroatom substituted derivatives may lead to functional diversity that could be applied to screen for potential virulence inhibitors. We thus synthesized a library of non-natural quinolone derivatives and report here the discovery of a potent inhibitor of the virulence factor elastase of pathogenic *P. aeruginosa*.

While previous studies have aimed to chemically inhibit or deregulate the *pqs* quorum sensing system using derivatives with modifications on the 2-alkyl-4-quinolone scaffold,<sup>18–20</sup> we focussed on the synthetically more demanding approach of systematically changing the core scaffold by substituting its functional groups and replacing its heteroatoms. We thereby aimed to explore the chemical space of the privileged structures of HHQ and PQS-like non-quinolone compounds and investigate their biological activity as potential virulence inhibitors of *P. aeruginosa*. We first developed and evaluated various synthetic strategies towards the quinolone scaffold whereby we obtained PQS and HHQ as control compounds. HHQ (1) was prepared as reported previously by the synthesis of 3-oxodecanoic acid methyl ester, condensation with aniline and subsequent Conrad-Limpach cyclization (Fig. 1A).<sup>21</sup> Although, HHQ was often used as starting point for the synthesis of 2-heptyl-3-hydroxyquinolin-4-one (PQS) by Duff-formylation and Dakin-oxidation as described by Pesci *et al.*,<sup>22</sup> both reactions appeared to be problematic.<sup>21</sup> Formylation of HHQ was only obtained when the HHQ was previously transferred into its quinoline tautomer. The following oxidation gave PQS in only 23% yield. PQS was therefore synthesized after the method of Hradil *et al.* which turned out to be a much more reliable and up scalable approach to prepare PQS (Fig. 1B).<sup>23,24</sup>

To generate a structurally diverse library of HHQ and PQS derivatives, heteroatom substitutions were intended at positions 1, 3, and 4 of the 2-alkyl-4-quinolone scaffold. 4-Thioketo-analogues 7 and 8 were synthesized by thionation of the appropriate

Department of Chemistry, Konstanz Research School Chemical Biology, University of Konstanz, 78457 Konstanz, Germany. E-mail: Thomas.Boettcher@uni-konstanz.de  
<sup>†</sup> Electronic supplementary information (ESI) available. See DOI: 10.1039/c6cc06295d






Fig. 1 Synthetic library of HHQ and PQS derivatives. (A) Synthesis scheme for HHQ (**1**) and the derived thioneketone **7**, and (B) for PQS (**2**) and its analog **8**. (C) Synthesis of compounds **3–6**. (D) Structures of the compound library tested in the bioassays.

4-keto-compounds HHQ (**1**) and PQS (**2**) using P<sub>2</sub>S<sub>10</sub> in pyridine under reflux conditions (Fig. 1A and B).<sup>25</sup> This reaction was found to be extremely reliable giving the desired products in good yields without interfering with hydroxyl- or amine functionalities at the same time whereas the Lawesson's reagent did not result in successful thionation of the ketones.

Chromen-4-one (**3**) and thiochromen-4-one (**4**) were synthesized from their corresponding 1,3-diketones **3b** and **4c** which were prepared by Baker–Venkataraman rearrangement of the octanoyloxy esters of 2-hydroxyacetophenone and 2-mercaptopacetophenone **4a**, respectively.<sup>26,27</sup> Synthesis of the 1-O and 1-S-PQS-derivatives **5** and **6** started from 2-hydroxy- and 2-mercaptopacetophenone, respectively *via* the corresponding chroman-4-one **5a** and thiochroman-4-one **6a** by pyrrolidine catalyzed Knoevenagel-reaction with octanal (Fig. 1C).<sup>28,29</sup> Oxidation of the  $\alpha$ -keto position turned out to be difficult since an oxidation of the sulfide group to a sulfoxide or sulfone had to be avoided. The product was obtained by nitrosation with isoamyl nitrite and subsequent oximation and oxime hydrolysis.<sup>29</sup> The combination of these diverse synthetic strategies resulted in a small library of 10 compounds (Fig. 1D). In order to investigate our library for potential biological activity we performed a series of virulence assays with live cells of the highly virulent *P. aeruginosa* strain PA14.<sup>30</sup> We screened the library for inhibition of three important extracellular virulence factors, pyocyanine, rhamnolipid, and elastase. Cultures of *P. aeruginosa* PA14 were grown in liquid medium supplemented with 500  $\mu$ M of each compound and after incubation for 24 h the production or activities of the




Fig. 2 Active compound screening and investigations on the mechanism of **8**. (A) Screening of the compound library for the effect on elastin–congo red degradation with DMSO as control. (B) *In vitro* inhibition of elastase activity by **8**. (C) <sup>1</sup>H NMR shifts of **8** in dependence of equivalents of added zinc(II). (D) Relative fluorescence increase of **8** in dependence of the zinc(II) concentration. Inset: Fluorescence of **8** under excitation by UV light at 365 nm. \*\*\* Independent two-sample *t*-test  $p < 0.00001$ .

corresponding virulence factors were quantified in spent culture supernatants.

While most compounds did not result in significant changes or slightly increased elastolytic activity (**2** and **6**), one compound (**8**) almost completely inhibited elastin degradation at a concentration of 500  $\mu$ M (Fig. 2A and Fig. S1, S2, ESI<sup>†</sup>). The active compound did not inhibit growth of *P. aeruginosa* at the maximum tested concentration of 1 mM indicating that the effect on was not an artefact of cell toxicity or reduced growth (Fig. S3, ESI<sup>†</sup>). Elastolytic activity in cultures of *P. aeruginosa* is mainly caused by the extracellular virulence factor LasB (elastase), a zinc metalloprotease that contributes as major virulence factor to the infectious lifestyle of *P. aeruginosa*.<sup>31</sup> As no other virulence factors tested were impacted, we speculated that coincidentally **8** may inhibit directly the activity of the enzyme elastase rather than its production *via* the *pqs* quorum sensing system. To test this hypothesis we used purified elastase and employed an activity assay with a fluorogenic peptide substrate. This *in vitro* assay resulted in a very potent inhibition by **8** with an IC<sub>50</sub> of 4  $\mu$ M, confirming the direct mode of inhibition of elastolytic activity on enzyme level (Fig. 2B).

It is known that analogous structures of **8** bind to zinc and are metalloproteinase inhibitors and PQS is known as iron chelator.<sup>32–35</sup> We thus speculated that the mechanism of action of **8** may involve binding to the zinc ion in the active site of elastase whereby its activity is inhibited. To investigate if **8** directly binds to zinc(II), we applied a combination of spectroscopic and NMR-based methods. NMR-titration of **8** with zinc chloride in DMSO resulted in significant shifts and broadening of <sup>1</sup>H and <sup>13</sup>C signals in dependence of the zinc(II) concentration (Fig. 2C and Fig. S4, S5, ESI<sup>†</sup>). Surprisingly, when zinc(II) was added to a solution of **8** in ethanol, a strong fluorescence was observed and a titration experiment revealed that zinc concentrations down to 2.5  $\mu$ M could still be detected by fluorescence

intensities two-fold over baseline making the compound also a formidable zinc sensor (Fig. 2D). In contrast, no fluorescence was observed for other biologically relevant divalent cations, confirming its high selectivity for zinc. These results suggest that **8** inhibits elastase by binding to the zinc ion in active site of this metalloenzyme.

In order to further elucidate the influence of heteroatoms in position 1 for elastase inhibition, we synthesized a second generation of analogues of **8** including derivatives with the nitrogen in position 1 of the 3-hydroxy-4-thioquinolone scaffold replaced by oxygen **9** and sulphur **10**. Additionally we generated a 3-hydroxy-4-oxime derivative as an alternative metal chelator (**11**). The 4-thioketones **9** and **10** were synthesized by thionation with  $P_4S_{10}$  in pyridine as described for **7** and **8** (Fig. 3A). Interestingly, the oxime **11** could not be obtained by base catalyzed reaction of PQS with hydroxylamine hydrochloride which is probably because the keto-form can be also understood as vinyllogous amide<sup>36</sup> instead, 3-hydroxyl TBDMS protected PQS was transferred into its enol-tautomer and 4-hydroxyl benzylated to allow the oxime formation at position 4 (Fig. 3B).

Using this set of compounds, we first investigated their ability to inhibit elastase activity *in vitro*. Hereby, compounds **9** and **10** were even slightly more active than **8**, each with an  $IC_{50}$  of 2  $\mu$ M (Fig. 4A and Fig. S6, ESI<sup>†</sup>). In contrast, compound **11** did not inhibit elastase activity *in vitro* at concentrations up to 50  $\mu$ M indicating that sulphur in position 4 is required for activity of the compound and cannot be simply replaced by other chelating groups (Fig. S7, ESI<sup>†</sup>). While compounds **9** and **10** did not exhibit fluorescence in presence of zinc, a competitive spectroscopic experiment with **8** as zinc sensor allowed to detect fluorescence quenching at increasing concentrations of **9** and **10**, indicating that these compounds competed with **8** for zinc binding (Fig. S8, ESI<sup>†</sup>). Consequently, the inhibition of elastase involved most likely for all three compounds the binding of a hydroxyl thioketone or its corresponding thienol-form to the active site zinc. For the *in vitro* studies the higher activity of the electron deficient aromatic systems of compounds **9** and **10** first appeared to be puzzling. However, analysis of the crystal structure of elastase revealed a carboxyl group (Glu141) in proximity to the active site which might stabilize the positive charge in the thienol-form (Fig. 4B). Hydrophobic pockets in proximity to the active site appear to be ideal for accommodating the lipophilic heptyl chain of our compounds and also may




Fig. 4 Inhibition of *Pseudomonas* elastase activity. (A) Activity of the second generation of compounds derived from **8** with elastase *in vitro*. (B) Active site of LasB with His140, His144, and Glu164 coordinating the zinc ion and proposed mechanism of inhibition. (C) *In situ* inhibition of elastolytic activity with compound **8** in culture of *P. aeruginosa* PA14.

explain the preference for hydrophobic side groups in natural substrates and previously reported elastase inhibitors.<sup>34,37,38</sup>

To quantify the *in situ* efficacy, we measured the concentration dependent inhibition of elastolytic activity by compounds **8–11** with live cultures of *P. aeruginosa* PA14. Hereby, only compound **8** was an efficient inhibitor of elastolytic activity *in situ* resulting in sigmoidal inhibition behaviour with an  $IC_{50}$  of 40  $\mu$ M (Fig. 4C). Compound **10** resulted in only low efficacy with an *in situ*  $IC_{50}$  of 351  $\mu$ M and compounds **9** and **11** were inactive up to 500  $\mu$ M (Fig. S9, ESI<sup>†</sup>). The discrepancy between *in vitro* and *in situ* activity of **9** and **10** may be explained by their similarity to flavones that are known to be degraded by *Pseudomonads*.<sup>39</sup> We thus suspect that the compounds may be fed into bacterial metabolism reducing their half-life and thus their efficacy whereby the magnitude of the drop in activity from *in vitro* to *in situ* experiments correlates with the increasing similarity of the compounds with the flavone scaffold. With **8** being the most active compound *in situ* we have discovered a potent inhibitor of Elastase (LasB) as major virulence factor of *P. aeruginosa* PA14 that is responsible for the pathogen's ability to evade the immune response and establish life-threatening infections.<sup>40,41</sup>

In conclusion, PQS derived quinolones with heteroatom substitutions represent highly interesting privileged structures that can be easily accessed by organic synthesis. Specifically, we demonstrate that 3-hydroxy-4-thioquinolone derivatives are promising candidates for the development of customized elastase inhibitors. We show evidence that our most active compound binds directly to the active site zinc of the enzyme and inhibits elastolytic activity *in vitro* and also in cultures of live cells. Our newly developed core scaffold thus represents an unprecedented chemical tool for studying elastase function and highly promising lead structure for further development of potential anti-virulence drugs.

We thank Prof. Andreas Marx and his group for their generous support. We gratefully acknowledge funding by the




Fig. 3 Synthesis of a second generation of compounds based on the active elastase inhibitor **8**. (A) Scheme for the synthesis of the thioquinolone derivatives **9** and **10**, and (B) for the oxime **11**.



Emmy Noether program of the Deutsche Forschungsgemeinschaft (DFG), EU FP7 Marie Curie Zukunftskolleg Incoming Fellowship Program – University of Konstanz grant no. 291784, Fonds der Chemischen Industrie (FCI), Konstanz Research School Chemical Biology (KoRS-CB), and CRC969 (DFG). DS was supported by a KoRS-CB PhD fellowship. We thank PD Dr David Schleheck and Prof. Christof Hauck for the use of their S2 facilities, and Atul Pawar for help with Pymol.

## Notes and references

1. A. Oliver, R. Canton, P. Campo, F. Baquero and J. Blazquez, *Science*, 2000, **288**, 1251–1254.
2. G. P. Bodey, R. Bolivar, V. Fainstein and L. Jadeja, *Rev. Infect. Dis.*, 1983, **5**, 279–313.
3. V. Aloush, S. Navon-Venezia, Y. Seigman-Igra, S. Cabili and Y. Carmeli, *Antimicrob. Agents Chemother.*, 2006, **50**, 43–48.
4. T. Strateva and I. Mitov, *Ann. Microbiol.*, 2011, **61**, 717–732.
5. B. Wretblad and O. R. Pavlovskis, *Rev. Infect. Dis.*, 1983, **5**(suppl. 5), S998–S1004.
6. R. S. Smith and B. H. Iglesias, *Curr. Opin. Microbiol.*, 2003, **6**, 56–60.
7. M. Schuster and E. P. Greenberg, *Int. J. Med. Microbiol.*, 2006, **296**, 73–81.
8. M. A. Welsh and H. E. Blackwell, *Cell Chem. Biol.*, 2016, **23**, 361–369.
9. M. A. Welsh, N. R. Eibergen, J. D. Moore and H. E. Blackwell, *J. Am. Chem. Soc.*, 2015, **137**, 1510–1519.
10. Q. H. Christensen, T. L. Grove, S. J. Booker and E. P. Greenberg, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 13815–13820.
11. T. Böttcher and S. A. Sieber, *J. Am. Chem. Soc.*, 2008, **130**, 14400–14401.
12. J. D. Moore, F. M. Rossi, M. A. Welsh, K. E. Nyffeler and H. E. Blackwell, *J. Am. Chem. Soc.*, 2015, **137**, 14626–14639.
13. S. McGrath, D. S. Wade and E. C. Pesci, *FEMS Microbiol. Lett.*, 2004, **230**, 27–34.
14. E. Deziel, F. Lepine, S. Milot, J. He, M. N. Mindrinos, R. G. Tompkins and L. G. Rahme, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 1339–1344.
15. H. Huse and M. Whiteley, *Chem. Rev.*, 2011, **111**, 152–159.
16. J. F. Dubern and S. P. Diggle, *Mol. BioSyst.*, 2008, **4**, 882–888.
17. M. W. Calfee, J. P. Coleman and E. C. Pesci, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 11633–11637.
18. M. Starkey, F. Lepine, D. Maura, A. Bandyopadhyaya, B. Lesic, J. X. He, T. Kitao, V. Righi, S. Milot, A. Tzika and L. Rahme, *PLoS Pathog.*, 2014, **10**, e1004321.
19. C. Lu, B. Kirsch, C. K. Maurer, J. C. de Jong, A. Braunshausen, A. Steinbach and R. W. Hartmann, *Eur. J. Med. Chem.*, 2014, **79**, 173–183.
20. A. Ilangovan, M. Fletcher, G. Rampioni, C. Pustelny, K. Rumbaugh, S. Heeb, M. Camara, A. Truman, S. R. Chhabra, J. Emsley and P. Williams, *PLoS Pathog.*, 2013, **9**, e1003508.
21. F. J. Reen, S. L. Clarke, C. Legendre, C. M. McSweeney, K. S. Eccles, S. E. Lawrence, F. O'Gara and G. P. McGlacken, *Org. Biomol. Chem.*, 2012, **10**, 8903–8910.
22. E. C. Pesci, J. B. Milbank, J. P. Pearson, S. McKnight, A. S. Kende, E. P. Greenberg and B. H. Iglesias, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 11229–11234.
23. P. Hradil, J. Hlavac and K. Lemr, *J. Heterocycl. Chem.*, 1999, **36**, 141–144.
24. J. T. Hodgkinson, W. R. J. D. Galloway, S. Saraf, I. R. Baxendale, S. V. Ley, M. Ladlow, M. Welch and D. R. Spring, *Org. Biomol. Chem.*, 2011, **9**, 57–61.
25. J. Bergman, B. Pettersson, V. Hasimbegovic and P. H. Svensson, *J. Org. Chem.*, 2011, **76**, 1546–1553.
26. P. Nanjan, J. Nambiar, B. G. Nair and A. Banerji, *Bioorg. Med. Chem.*, 2015, **23**, 3781–3787.
27. J. I. Lee and M. J. Kim, *Bull. Korean Chem. Soc.*, 2011, **32**, 1383–1386.
28. H. J. Kabbe and A. Widdig, *Angew. Chem., Int. Ed.*, 1982, **21**, 247–256.
29. M. Ferrali, S. Bambagioni, A. Ceccanti, D. Donati, G. Giorgi, M. Fontani, F. Laschi, P. Zanello, M. Casolaro and A. Pietrangelo, *J. Med. Chem.*, 2002, **45**, 5776–5785.
30. H. Mikkelsen, R. McMullan and A. Filloux, *PLoS One*, 2011, **6**, e29113.
31. D. R. Galloway, *Mol. Microbiol.*, 1991, **5**, 2315–2321.
32. S. Johnson, E. Barile, B. Farina, A. Purves, J. Wei, L. H. Chen, S. Shiryayev, Z. Zhang, I. Rodionova, A. Agrawal, S. M. Cohen, A. Osterman, A. Strongin and M. Pellecchia, *Chem. Biol. Drug Des.*, 2011, **78**, 211–223.
33. A. Agrawal, S. L. Johnson, J. A. Jacobsen, M. T. Miller, L. H. Chen, M. Pellecchia and S. M. Cohen, *ChemMedChem*, 2010, **5**, 195–199.
34. A. L. Garner, A. K. Struss, J. L. Fullagar, A. Agrawal, A. Y. Moreno, S. M. Cohen and K. D. Janda, *ACS Med. Chem. Lett.*, 2012, **3**, 668–672.
35. S. P. Diggle, S. Matthijs, V. J. Wright, M. P. Fletcher, S. R. Chhabra, I. L. Lamont, X. Kong, R. C. Hider, P. Cornelis, M. Camara and P. Williams, *Chem. Biol.*, 2007, **14**, 87–96.
36. S. Hibino, E. Sugino, T. Choshi and K. Sato, *J. Chem. Soc., Perkin Trans. 1*, 1988, 2429–2432.
37. G. R. Cathcart, D. Quinn, B. Greer, P. Harriott, J. F. Lynas, B. F. Gilmore and B. Walker, *Antimicrob. Agents Chemother.*, 2011, **55**, 2670–2678.
38. N. Nishino and J. C. Powers, *J. Biol. Chem.*, 1980, **255**, 3482–3486.
39. B. V. Pillai and S. Swarup, *Appl. Environ. Microbiol.*, 2002, **68**, 143–151.
40. M. J. van der Plas, R. K. Bhongir, S. Kjellstrom, H. Siller, G. Kasetty, M. Morgelin and A. Schmidtchen, *Nat. Commun.*, 2016, **7**, 11567.
41. Z. Kuang, Y. Hao, B. E. Walling, J. L. Jeffries, D. E. Ohman and G. W. Lau, *PLoS One*, 2011, **6**, e27091.

